50 results
6-K
EX-99.3
SCNI
Scinai Immunotherapeutics Ltd
2 Oct 20
Condensed Interim Financial Statements
12:00am
at favorable reimbursement rates. The degree of market acceptance of these products will depend on a number of factors, including, but not limited … and success of our distribution, sales and marketing efforts; and
the pricing, coverage and reimbursement policies of government and third-party
10-K
2022 FY
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
business.
Coverage and Reimbursement
Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third … , and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided
6-K
EX-99.1
4f5sp typ0bsnu
10 Nov 22
Current Report
5:28pm
424B5
wex08c7
28 Dec 21
Prospectus supplement for primary offering
5:20pm
424B5
il99nw15hz0bm
27 Dec 21
Prospectus supplement for primary offering
6:22am
424B5
dnaiaqz 2wgl67eb30z
1 Feb 21
Prospectus supplement for primary offering
5:08pm
424B5
g3px6t84bd9vcqewi6gf
29 Jan 21
Prospectus supplement for primary offering
12:00am
F-1
EX-10.13
r44hr37h7zp
29 Dec 14
Registration statement (foreign)
12:00am
424B5
gfr cn93c6obn9jpdes
2 Oct 20
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
r2mzngq 8z
22 Nov 21
Report of Foreign Private Issuer
6:05am
POS AM
3ltuu408d1
7 Jan 20
Prospectus update (post-effective amendment)
10:51am
F-1
t5lyw os07ktp3y
29 Dec 14
Registration statement (foreign)
12:00am
F-1
EX-10.12
9l8r trxoqw
29 Dec 14
Registration statement (foreign)
12:00am
6-K
EX-99.1
571lu
4 Mar 21
Report of Foreign Private Issuer
1:01pm